Taking stock: An assessment of 2020 for the EU5 pharma market, and the lessons for 2021 - Iqvia
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Taking stock: An assessment of 2020 for the EU5 pharma market, and the lessons for 2021 Sarah Rickwood & Natalie Harb Webinar: September 29, 2020 © 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
IQVIA speakers for today’s session
Sarah Rickwood, Natalie Harb
Vice President, Senior Principal,
European Marketing and Thought Leadership Global Analytics Solutions
© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. 1Agenda
1 Taking stock: An assessment of 2020 for the EU5 pharma market
2 Latest Sales Trends & HCP engagement across the EU5 Countries
3 Lessons for 2021
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 2Where is the world in the COVID-19 pandemic?
Over 40% of the global population lives in countries past the initial peak
Not yet peaked Peaked but not yet at < Less than Experiencing second wave
20% of peak 20% of peak or signs of a rebound
Countries: 34 Countries: 51 Population: Countries: 52 Countries: 42
Population: 2.3bn 2.0bn. Population: 2.5bn Population: 0.8bn
• Most South American • Joint most African • Most Central • Joint most African • Most European and Oceania countries
countries countries American, Eastern countries • Canada, Australia, UK, Japan
• India, Syria, Peru European, and • Most Asian and
Middle Eastern Caribbean countries
countries • Italy, Portugal, Thailand
• US, Brazil, Iran,
Mexico
30% 27% 33% 10%
population population population population
Source: IQVIA European Thought Leadership estimations based on World Bank population data, John Hopkins University ("Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time.
Lancet Inf Dis. 20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1“)
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 3COVID-19 has induced a significant fluctuation in pharma sales across the
globe with varying impact across drug classes
Global Pharma Sales in Standard Units – Retail + Hospital market
Global Pharma sales (Bn SU/day) Global MoM growth baselined vs. Change in YTD sales 2019 vs. 2020 (%)
average MoM growth 2015-2020
-1.3%
6.5 1,054
6.0
5.5
1,040
5.0
0.0
Jan-15
Jan-16
Jan-17
Jan-18
Jan-19
Jan-20
Jun-20
Jul-15
Jul-16
Jul-17
Jul-18
Jul-19
Jul-20
Jan-15
Jan-16
Jan-17
Jan-18
Jan-19
Jan-20
2019 2020
• Increased use of generic medicines during the COVID-19 • Biologic medicines and branded drug sales have seen
pandemic could reflect a shift in healthcare priorities reduced use during the COVID-19 pandemic
• COVID-19 occurred in the same period as a shift towards • Impact of COVID-19 is most pronounced in primary care
biosimilars but it may be a coincidence medicine usage
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 4In terms of overall pharma sales, both the US and EU5 have experienced
similar peaks mid-pandemic
Pharma Sales in Standard Units – Retail + Hospital market
US Pharma sales (Mn SU/day) EU5 Pharma sales (Mn SU/day)
1,000 1,000
800 800
600 600
400 400
200 200
0 0
Jan-19 Mar-19 May-19 Jul-19 Sep-19 Nov-19 Jan-20 Mar-20 May-20 Jul-20 Jan-19 Mar-19 May-19 Jul-19 Sep-19 Nov-19 Jan-20 Mar-20 May-20 Jul-20
US quarterly peak magnitude baselined vs. Avg 2015-2020 EU5 MoM baselined vs. Avg MoM 2015-2020
Jan- Jan- Jan- Jan- Jan- Jan-
Q1 Q1 Q1 Q1 Q1 Q1 15 16 17 18 19 20
2015 2016 2017 2018 2019 2020
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 5There was a proportional increase in specialty and small molecule spend
which was highest in the UK
Absolute difference (Jan-Jun 2020 v/s Jan-Jun 2019) in LCEuros Mn
Specialty Traditional Biologics Small Molecules
€650Mn -€98Mn €487Mn €65Mn
€1,170Mn €376Mn €903Mn €644Mn
€90Mn -€219Mn €136Mn -€265Mn
€451Mn €109Mn €249Mn €310Mn
€758Mn €110Mn €339Mn €529Mn
France Germany Italy Spain UK
Period on Period growth % LCEuro Period on Period growth % LCEuro
(Jan-Jun 2020 v/s Jan-Jun 2019) (Jan-Jun 2020 v/s Jan-Jun 2019)
FRA GER ITA SPA UK FRA GER ITA SPA UK
Max. growth
Specialty 9% 11% 1% 9% 14% Biologics 10% 11% 3% 8% 10%
Min. Growth
Traditional -1% 4% -3% 2% 2% Small Mol. 1% 6% -3% 4% 7%
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 6Hospital and retail have shown different responses to COVID crisis; hospital
value growth despite volume falls
Hospital Retail
Value: Difference in YTD sales 2020-2019 (Mn LCEuro Jan-Jun, Abs) Value: Difference in YTD sales 2020-2019 (Mn LCEuro Jan-Jun, Abs)
679 1,389
443
368
158 184 116 189
49
-178
France Germany Italy Spain UK
France Germany Italy Spain UK
Volume: Difference in YTD sales 2020-2019 (Mn SU Jan-Jun, Abs) Volume: Difference in YTD sales 2020-2019 (Mn SU Jan-Jun, Abs)
853
209
-157 -142
-168
-193 -22
-203
-279 -407
France Germany Italy Spain UK France Germany Italy Spain UK
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 7Preliminary data shows recovery across Hospital and Retail in June
Hospital Retail
Value: EU5 Hospital 2020 vs. same period 2019 (LCEuro %) Value: EU5 Retail 2020 vs. same period 2019 (LCEuro %)
30 30
20 20
10
10
0
0
-10
-10 -20
-20 -30
Jan Feb Mar Apr May Jun Jan Feb Mar Apr May Jun
Volume: EU5 Hospital 2020 vs. same period 2019 (Standard Units %) Volume: EU5 Retail 2020 vs. same period 2019 (Standard Units %)
20 30
0 20
10
-20
0
-40 -10
-60 -20
Jan Feb Mar Apr May Jun Jan Feb Mar Apr May Jun
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020 France Germany Italy Spain UK
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 8The UK leads the EU5 in proportional value increase and volume decrease
during the pandemic
Hospital Retail
Value: Difference in YTD sales 2020-2019 (LCEuro Jan-Jun, %) Value: Difference in YTD sales 2020-2019 (LCEuro Jan-Jun, %)
11.3% 8.3%
7.9% 4.2%
6.9%
5.3% 2.1% 2.4%
0.5%
-3.9%
France Germany Italy Spain UK
France Germany Italy Spain UK
Volume: Difference in YTD sales 2020-2019 (SU Jan-Jun, %) Volume: Difference in YTD sales 2020-2019 (SU Jan-Jun, %)
3.0%
-5.2% 0.7%
-8.9% -0.1%
-11.0%
-13.1% -1.0%
-14.7% -1.7%
France Germany Italy Spain UK France Germany Italy Spain UK
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 9For most primary care pattern across countries is similar; more divergence
in specialty
Value: EU5 Oncology 2020 vs. same period Value: EU5 Immunology 2020 vs. same period Value: EU5 Anticoagulants 2020 vs. same
2019 (LCEuro %) 2019 (LCEuro %) period 2019 (LCEuro %)
40 40 40
30 30 30
20 20
20
10 10
10
0 0
-10 -10 0
-20 -20 -10
Jan Feb Mar Apr May Jun Jan Feb Mar Apr May Jun Jan Feb Mar Apr May Jun
Value: EU5 Antidiabetics 2020 vs. same period Value: EU5 Pain 2020 vs. same period 2019
2019 (LCEuro %) (LCEuro %)
40 30
30 20
20 10
10 0
0 -10
-10 -20
-20 -30
Jan Feb Mar Apr May Jun Jan Feb Mar Apr May Jun
France Germany Italy Spain UK
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 10Looking specifically at the anti-coagulant market – in the US, NOACs grew
significantly vs. warfarin while in the EU5 both categories grew strongly
NOAC (Novel Oral Anti-Coagulants) and Warfarin Sales in Standard Units – Retail + Hospital market
US NOAC quarterly difference EU5 MoM NOAC growth • US use of NOACs has increased
baselined 2015-2020 baselined 2015-2020 during the COVID-19 pandemic, likely
due to demand for self-administered
anti-coagulants
• EU5 anti-coagulant use has not been
impacted by COVID-19 in a way which
favours self-administration
US Warfarin quarterly difference baselined EU5 MoM Warfarin growth baselined
2015-2020 2015-2020 • Both NOACs and warfarin growth
peaked in March 2020
Warfarin requires regular blood monitoring
unlike NOACs, leading to varying preference
towards NOACs during COVID-19 period
across countries
Sep-15
Dec-15
Sep-16
Dec-16
Sep-17
Dec-17
Sep-18
Dec-18
Sep-19
Dec-19
Sep-15
Dec-15
Sep-16
Dec-16
Sep-17
Dec-17
Sep-18
Dec-18
Sep-19
Dec-19
Jun-15
Jun-16
Jun-17
Jun-18
Jun-19
Jun-20
Jun-15
Jun-16
Jun-17
Jun-18
Jun-19
Jun-20
Mar-15
Mar-16
Mar-17
Mar-18
Mar-19
Mar-20
Mar-15
Mar-16
Mar-17
Mar-18
Mar-19
Mar-20
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 11While within the EU5, local country policies appear to have created a varying
impact on anti-coagulant use during the pandemic
NOAC (Novel Oral Anti-Coagulants) and Warfarin Sales in Standard Units – Retail + Hospital market
Anti-coagulant usage in Italy Anti-coagulant usage in Germany Anti-coagulant usage in Spain
(Mn SU/day) (Mn SU/day) (Mn SU/day)
1.5 4.5 0.8
4.0
0.6
1.0 3.5
3.0 0.4
0.5
2.5 0.2
0.0 0.0 0.0
Mar-18
Sep-18
Mar-19
Sep-19
Mar-20
Mar-18
Sep-18
Mar-19
Sep-19
Mar-20
Mar-18
Sep-18
Mar-19
Sep-19
Mar-20
Nov-18
Nov-19
Nov-18
Nov-19
Nov-18
Nov-19
May-18
Jul-18
May-19
Jul-19
May-20
Jul-20
May-18
Jul-18
May-19
Jul-19
May-20
Jul-20
May-18
Jul-18
May-19
Jul-19
May-20
Jul-20
Jan-18
Jan-19
Jan-20
Jan-18
Jan-19
Jan-20
Jan-18
Jan-19
Jan-20
Anti-coagulant usage in France Anti-coagulant usage in UK
(Mn SU/day) (Mn SU/day)
2.5 2.0
2.0 1.5
1.5 1.0
0.5 0.5
0.0 0.0
Mar-18
Mar-19
Mar-20
Mar-18
Mar-19
Mar-20
Sep-18
Nov-18
Sep-19
Nov-19
Sep-18
Nov-18
Sep-19
Nov-19
Jul-18
Jul-19
Jul-20
Jul-18
Jul-19
Jul-20
Jan-18
May-18
Jan-19
May-19
Jan-20
May-20
Jan-18
May-18
Jan-19
May-19
Jan-20
May-20
NOAC Warfarin
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 12IQVIA’s MIDAS data has tracked very different New Active Substance launch
activity across major countries in 2020
Lockdown* announced – 21/Mar Lockdown* announced – 20/Mar Lockdown* announced – 14/Mar
50 US 50 Germany 50 Spain
45
40 40 33 40
32
30 30 30
22
20 20 13 20 15
Number of NAS launches
16
10 10 10 9
12
0 0 0
May
May
May
Nov
Nov
Nov
Feb
Feb
Feb
Aug
Sep
Aug
Sep
Aug
Sep
Jul
Jul
Jul
Jan
Mar
Jun
Oct
Jan
Mar
Jun
Oct
Jan
Mar
Jun
Oct
Apr
Dec
Apr
Dec
Apr
Dec
2015-19 avg 2020 2015-19 avg 2020 2015-19 avg 2020
Lockdown* announced – 16/Mar Lockdown* announced – 21/Feb Lockdown* announced – 23/Mar
50 France 50 Italy 50 UK
40 40 40
32
30 30 30
27 32
15 18
20 20 20 14
10 14 10 14 10
6
0 0 0
May
May
May
Nov
Nov
Nov
Feb
Aug
Sep
Feb
Aug
Sep
Feb
Aug
Sep
Jul
Jul
Jul
Jan
Mar
Jun
Jan
Mar
Oct
Jan
Mar
Jun
Oct
Jun
Oct
Dec
Dec
Dec
Apr
Apr
Apr
2015-19 avg 2020 2015-19 avg 2020 2015-19 avg 2020
Source: MIDAS monthly May 2020, secondary research; Note: *California first state in the US to announce lockdown, Bavaria and Saarland are the first two states in Germany to impose lockdowns, at least ten towns in the
Lombardy and Veneto regions of Italy were first to announce lockdown
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 13Agenda
1 Taking stock: An assessment of 2020 for the EU5 pharma market
2 Latest Sales Trends & HCP engagement across the EU5 Countries
3 Lessons for 2021
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 14Unfortunately it seems like the second wave of COVID-19 is emerging
across Europe
Number of Reported COVID-19 Infections in EU5
Total confirmed COVID-19 cases 7-day moving total of new COVID-19 cases
700 80
600
60
500
400
Thousands
Thousands
40
300
200
20
100
0 0
15-Sep
11-Aug
18-Aug
25-Aug
2-Jun
9-Jun
7-Jul
5-May
3-Mar
14-Apr
21-Apr
28-Apr
8-Sep
25-Feb
7-Apr
16-Jun
23-Jun
30-Jun
14-Jul
21-Jul
28-Jul
4-Aug
1-Sep
12-May
19-May
26-May
10-Mar
17-Mar
24-Mar
31-Mar
7-Jul
2-Jun
9-Jun
3-Mar
5-May
11-Aug
18-Aug
25-Aug
15-Sep
7-Apr
14-Apr
21-Apr
28-Apr
4-Aug
1-Sep
8-Sep
25-Feb
16-Jun
23-Jun
30-Jun
14-Jul
21-Jul
28-Jul
31-Mar
10-Mar
17-Mar
24-Mar
12-May
19-May
26-May
Italy Germany Spain France UK Italy Germany Spain France UK
^CFR (Case Fatality Rate) is the ratio of the number of COVID-19 reported deaths to the total number of reported confirmed cases. However, this largely varies with the diagnosis rate and the testing performed by each
country; *As of 25th August, **As of 27th August, Data last 30 days; Sources provided in Appendix section
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 15The younger age cohort are getting infected now during the 2nd wave
compared to the older population at the start of the pandemic
COVID-19 reported infections in Italy COVID-19 reported infections in Germany
Split by age Split by age
Till 15th June 24th Aug – 6th Sept Till 16th June 7th Sept - 13th Sept
2% 7% 13% 7% 6%
19% 19%
29% 21% 18%
38%
43%
31%
31% 60%
57%
0-18 years 19-50 years 51-70 years >70 years 0-19 years 20-49 years 50-69 years >=70 years
COVID-19 reported infections in Spain COVID-19 reported infections in France
Split by age Split by age
Till 14th May 31st Aug - 6th Sept As of 16th June As of 15th Sept
1% 0.4% 1%
11% 13%
25%
30% 30%
37%
22% 47%
53%
21%
54% 23%
32%
0-14 years 15-49 years 50-69 years >=70 years 0-14 years 15-64 years 65-74 years >75 years
Sources provided in Appendix section
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 16EU5 Summary
Data Facts
COVID-19 Reported Numbers* EU5 Total YTD sales and market overview (v. PY) +4.9%
• Rx Market: Antineoplastic and Immunomodulating Highest volume growth in
Total Cases 1,944,759 agents (ATC L class) and Cardiovascular system (ATC ATC L class in Germany
C Class) show an increase in volume sales in most
New Cases 23,357 countries
• Hospital Market: Antineoplastic and
+10.6%
Deaths 147,506 Highest volume growth in
Immunomodulating agents (ATC L class) show an ATC L class in Spain
*As of 15th September increase in volume sales in most countries
YTD Volume Growth by Country • CH Market: Patient Care and Personal Care products
show positive YTD volume growth rate in most countries
+15.6%
Increase in volume of
with the highest growth reported in Italy for Patient Care Patient Care category in
Rx and in France for Personal Care Italy
market
growth
-4.3% -3.9% -3.5% -1.9% +0.2%
w37 w37 w37 w37 w37
+233%
Hosp. HCP engagement Increase (v. PY) in remote
market interactions in Spain. The
growth • The UK is the only county that has experienced an corresponding increase in
-13.0% -12.2%-11.2% -5.9% -3.4% increase in promotional contact this Sep vs. Italy (v. PY) is +160%
M7 M7 M7 M7 M7
CH Sept 2020
market • Face to face interactions shows a decrease in Italy,
growth Germany and Spain week-on-week
-5.1% -0.3% +0.5% +1.6% +2.3%
w37 w37 w37 w37 w37
ATC: Anatomical Therapeutic Chemical Classification; CH: Consumer Health; v. PY: versus Previous Year, M7: July 2020, w37: Week starting 7th September
*Source: Center for System Science and Engineering (CSSE) at John Hopkins University (JHU)
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 17France and Italy saw a spike at the start of August within the Retail market.
Within the Consumer Health market, UK saw a sharp decline at the end of
August
% Growth in Units – Rx retail market, Hospital market, Consumer Health market
Retail Rx market Hospital market Consumer Health market
% Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same
week 2019 in EU5 week 2019 EU5 week 2019 EU5
60% 40% 120%
50% 100%
30%
40%
% Growth – Units
% Growth – Units
% Growth – Units
80%
30% 20%
20% 60%
10%
10% 40%
0% 0%
20%
-10%
-10% 0%
-20%
-30% -20% -20%
-40%
-30% -40%
W11: 09-Mar
W13: 23-Mar
W37: 7-Sep
W19: 04-May
W21: 18-May
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W29: 13-Jul
W31: 27-Jul
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
W33: 10-Aug
W35: 24-Aug
W3: 13-Jan
W5: 27-Jan
W7: 10-Feb
W9: 24-Feb
W11: 09-Mar
W13: 23-Mar
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W37: 7-Sep
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
W29: 13-Jul
W31: 27-Jul
-40%
Mar
Apr
Jan
May
Jul
Jun
Feb
Week Starting Dates Month Week Starting Dates
Italy Germany Spain France UK
*Units Growth Latest week 2020 vs. 2019; Source: IQVIA weekly sell out data – Week 1 2020 starting 30/12/2019 | Retail pharmacy panel – captures sales of products at retail pharmacies
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 18F2F rep activity was replaced by remote contacts in April-May:
F2F rep activity started to recover in EU5, August showed holiday impact
EU5 – Number of face to face detailing and meeting contacts EU5 – Number of remote detailing and meeting contacts
4.5 1.4
4.2Mn
1.3
4.0
1.2
3.5 1.1
1.0
3.0 0.9Mn
0.9
2.5 2.3Mn 0.8
0.7
2.0 1.7Mn 0.6
1.5 1.3Mn 0.5
1.1Mn 0.4
1.0 0.3 0.2Mn
1.0Mn 0.3Mn
0.5Mn 0.2 0.2Mn
0.5 0.4Mn 0.5Mn 0.1Mn
0.1Mn 0.1 0.0Mn 0.2Mn
0.0 0.0 0.1Mn
May-2020
Aug-2020
Feb-2020
Mar-2020
Jun-2020
Jan-2020
Apr-2020
Feb-2020
Apr-2020
Jul-2020
Aug-2020
Jan-2020
May-2020
Jun-2020
Mar-2020
Jul-2020
0.1Mn
France Germany Italy Spain UK France Germany Italy Spain UK
Source: Channel Dynamics; F2F includes detailing and meetings; Jan – Aug 2020, compared with the same period in 2019
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 19We also see that nearly 40-50% of HCP’s in EU & US have indicated that
virtual interactions will be sufficient in the future
Ratings of HCP satisfaction with virtual detailing
HCP satisfaction with virtual detailing
Top 7 developed – July 2020
8.7%
18.3%
25.0% Thinking about a post-COVID-19 crisis context,
22.7% please indicate your level of agreement with the
following statement:
26.2%
28.9%
“Remote interactions with pharma representatives via
online tools such as Skype, Zoom, Webex… will be
sufficient in meeting my needs for up to date and relevant
68.6% drug treatment information”
55.5%
46.1% Scored 0-10
EU5 US Japan
Completely Agree (9-10) Somewhat Agree (7-8) Disagree (0-6)
Source: IQVIA Channel Dynamics Channel Preference Survey July 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 20The Italian prescription, hospital and consumer health markets have seen
signs of recovery in recent weeks
% Growth in Units – Rx retail market, Hospital market, Consumer Health market
Retail Rx market Hospital market Consumer Health market
% Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same
week 2019 Top 5* YTD month 2019 Top 5* YTD week 2019 Consumer health categories
120% 40% 120%
100% 30% 100%
80% 20% 80%
% Growth – Units
% Growth – Units
% Growth – Units
60% 10% 60%
40% 0% 40%
20% -10% 20%
0% -20% 0%
-20% -30% -20%
-40% -40% -40%
W11: 09-Mar
W13: 23-Mar
W37: 7-Sep
W3: 13-Jan
W5: 27-Jan
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
W29: 13-Jul
W31: 27-Jul
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
W11: 09-Mar
W13: 23-Mar
W37: 7-Sep
W3: 13-Jan
W5: 27-Jan
W21: 18-May
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W29: 13-Jul
W31: 27-Jul
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
Mar
Apr
Jan
May
Jun
Jul
Feb
Month
Week Starting Dates Week Starting Dates
Antineoplastic and immunomodulating agents
Antineoplastic and immunomodulating agents
Musculo-skeletal system Over-the-Counter Drugs (OTC)
Nervous system
Nervous system Personal Care (PEC)
Cardiovascular system
Systemic hormonal preparations… Systemic Anti-Infectives Patient Care (PAC)
Genito-urinary system and sex hormones Blood and blood forming organs Nutrition (NTR)
*Top in terms of YTD Growth; Units Growth Latest week 2020 vs. 2019; Source: IQVIA weekly sell out data – Week 1 2020 starting 30/12/2019 | Retail pharmacy panel – captures sales of products at retail pharmacies
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 21The overall promotional volume in Italy is still slightly lower (-9%) compared
to 2019 with F2F detailing recovering to 69% of total contact volume
Promotional volume share and growth
Promotional volume share by channel % Change in promotional volume by channel
September* 2019 – September* 2020
-30%
-15%
152%
69%
89% 171%
875%
177%
6%
9% 27%
channels
2%
total
3% 15%
All
-9%
1% 5% 1%
September September
2019 2020
F2F Detailing E-Detailing E-meetings Postal Mailing
F2F Meeting Phone Detailing E-mail
*30 day period to 13/09
Source: IQVIA European Thought Leadership; ChannelDynamics 13/09/2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 22In Germany, sales growth for the Dermatological class within Retail has
increased in recent weeks
% Growth in Units – Rx retail market, Hospital market, Consumer Health market
Retail Rx market Hospital market Consumer Health market
% Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same
week 2019 Top 5* YTD month 2019 Top 5* YTD week 2019 Consumer health categories
120% 15% 120%
100% 10% 100%
5%
80% 80%
% Growth – Units
% Growth – Units
% Growth – Units
0%
60% -5% 60%
40% -10% 40%
20% -15% 20%
-20%
0% 0%
-25%
-20% -30% -20%
-40% -35% -40%
Mar
Apr
May
Jan
Jun
Jul
Feb
W3: 13-Jan
W5: 27-Jan
W15: 06-Apr
W17: 20-Apr
W7: 10-Feb
W9: 24-Feb
W11: 09-Mar
W13: 23-Mar
W19: 04-May
W21: 18-May
W37: 7-Sep
W33: 10-Aug
W35: 24-Aug
W29: 13-Jul
W31: 27-Jul
W1: 30-Dec
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
-60%
W3: 13-Jan
W5: 27-Jan
W7: 10-Feb
W9: 24-Feb
W11: 09-Mar
W13: 23-Mar
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W37: 7-Sep
W29: 13-Jul
W31: 27-Jul
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
Month
Week Starting Dates
Antineoplastic and immunomodulating agents Antineoplastic and immunomodulating agents Week Starting Dates
Dermatologicals Blood and blood forming organs Over-the-Counter Drugs (OTC)
Cardiovascular system Systemic Anti-Infectives Personal Care (PEC)
Systemic hormonal preparations… Nervous system Patient Care (PAC)
Blood and blood forming organs Cardiovascular system Nutrition (NTR)
*Top in terms of YTD Growth; Units Growth Latest week 2020 vs. 2019; Source: IQVIA weekly sell out data – Week 1 2020 starting 30/12/2019 | Retail pharmacy panel – captures sales of products at retail pharmacies
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 23The overall promotional volume in Germany is nearly back to pre COVID-19,
with majority share contributed by Postal Mailing and E-mails
Promotional volume share and growth
Promotional volume share by channel % Change in promotional volume by channel
September* 2019 – September* 2020
-33%
23%
34% -56%
2% 1%
1%
385%
1% 1% 18%
11% 138%
1,238%
67%
53% 55%
2%
channels
total
All
-2%
September September
2019 2020
F2F Detailing E-Detailing E-meetings Postal Mailing
F2F Meeting Phone Detailing E-mail
*30 day period to 13/09
Source: IQVIA European Thought Leadership; ChannelDynamics 13/09/2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 24Over the past few weeks, the Spanish retail prescription market trends
have remained relatively unchanged while hospital market is increasing
% Growth in Units – Rx retail market, Hospital market, Consumer Health market
Retail Rx market Hospital market Consumer Health market
% Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same
week 2019 Top 5* YTD month 2019 Top 5* YTD week 2019 Consumer health categories
120% 40% 120%
100% 30% 100%
80% 20% 80%
% Growth – Units
% Growth – Units
% Growth – Units
60% 10% 60%
40% 0% 40%
20% -10% 20%
0% -20% 0%
-20% -30% -20%
W37: 7-Sep
W11: 09-Mar
W13: 23-Mar
W3: 13-Jan
W5: 27-Jan
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W29: 13-Jul
W31: 27-Jul
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
-40% -40%
-50% -60%
W11: 09-Mar
W13: 23-Mar
W37: 7-Sep
W3: 13-Jan
W5: 27-Jan
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W7: 10-Feb
W9: 24-Feb
W29: 13-Jul
W31: 27-Jul
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
Apr
May
Mar
Jan
Jun
Jul
Feb
Week Starting Dates Month
Nervous system Antineoplastic and immunomodulating agents Week Starting Dates
Antineoplastic and immunomodulating agents Dermatologicals Over-the-Counter Drugs (OTC)
Cardiovascular system Systemic Anti-Infectives Personal Care (PEC)
Alimentary tract and metabolism Genito-urinary system and sex hormones Patient Care (PAC)
Blood and blood forming organs Musculo-skeletal system Nutrition (NTR)
*Top in terms of YTD Growth; Units Growth Latest week 2020 vs. 2019; Source: IQVIA weekly sell out data – Week 1 2020 starting 30/12/2019 | Retail pharmacy panel – captures sales of products at retail pharmacies
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 25Spain’s overall promotional volume is much lower (-27%) as compared to the
same period in 2019
Promotional volume share and growth
Promotional volume share by channel % Change in promotional volume by channel
September* 2019 – September* 2020
-75%
29%
-58%
230%
84% 23% 366%
3,500%
26%
147%
1% 110%
channels
5% 19%
total
4%
All
6% -27%
1% 2%
September September
2019 2020
F2F Detailing E-Detailing E-meetings Postal Mailing
F2F Meeting Phone Detailing E-mail
*30 day period to 13/09
Source: IQVIA European Thought Leadership; ChannelDynamics 13/09/2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 26The French retail Rx market is relatively stable, except for trend breaks in
holiday weeks while hospital market has shown a decrease in July ‘20
% Growth in Units – Rx retail market, Hospital market, Consumer Health market
Retail Rx market Hospital market Consumer Health market
% Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same
week 2019 Top 5* YTD month 2019 Top 5* YTD week 2019 Consumer health categories
120% 20%
160%
100% 15% 140%
80% 10% 120%
% Growth – Units
% Growth – Units
% Growth – Units
5% 100%
60% 80%
0%
40% 60%
-5% 40%
20%
-10% 20%
0% -15% 0%
-20%
-20% -20% -40%
W3: 13-Jan
W5: 27-Jan
W11: 09-Mar
W13: 23-Mar
W37: 7-Sep
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W29: 13-Jul
W31: 27-Jul
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
-40% -25%
W37: 7-Sep
W11: 09-Mar
W13: 23-Mar
W3: 13-Jan
W5: 27-Jan
Mar
Apr
May
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W29: 13-Jul
W31: 27-Jul
W33: 10-Aug
W35: 24-Aug
Jan
Jun
Jul
W1: 30-Dec
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
Feb
Month
Week Starting Dates Week Starting Dates
Antineoplastic and immunomodulating agents Antineoplastic and immunomodulating agents
Blood and blood forming organs Alimentary tract and metabolism Over-the-Counter Drugs (OTC)
Cardiovascular system Cardiovascular system Personal Care (PEC)
Nervous system Blood and blood forming organs Patient Care (PAC)
Alimentary tract and metabolism Systemic Anti-Infectives Nutrition (NTR)
*Top in terms of YTD Growth; Units Growth Latest week 2020 vs. 2019; Source: IQVIA weekly sell out data – Week 1 2020 starting 30/12/2019 | Retail pharmacy panel – captures sales of products at retail pharmacies
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 27In France, the overall promotional volume is still lower (-9%) compared to
2019 with significant increase in share of E-mails (49%)
Promotional volume share and growth
Promotional volume share by channel % Change in promotional volume by channel
September* 2019 – September* 2020
-31%
32% -60%
42%
1% 1% 165%
3% 0%
2% 0% 1% 50%
260%
34% 49%
32%
-39%
channels
20%
total
All
13% -9%
September September
2019 2020
F2F Detailing E-Detailing E-meetings Postal Mailing
F2F Meeting Phone Detailing E-mail
*30 day period to 13/09
Source: IQVIA European Thought Leadership; ChannelDynamics 13/09/2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 28The UK prescription market has been quite stable over the past two months
while hospital market showed a sharp increase in the month of June 2020
% Growth in Units – Rx retail market, Hospital market, Consumer Health market
Retail Rx market Hospital market Consumer Health market
% Growth – Weekly Rx in 2020 vs. Avg. % Growth – Units in 2020 vs. same % Growth – Units in 2020 vs. same
weekly Rx in Jan 2020 month 2019 Top 5* YTD week 2019 Consumer health categories
120% Top 5* ATC classes 120% 120%
100% 100% 100%
80% 80% 80%
% Growth – Units
% Growth – Units
% Growth – Units
60% 60% 60%
40% 40% 40%
20% 20% 20%
0% 0% 0%
-20% -20% -20%
W19: 04-May
W21: 18-May
W33: 10-Aug
W35: 24-Aug
W37: 7-Sep
W7: 10-Feb
W9: 24-Feb
W11: 09-Mar
W13: 23-Mar
W15: 06-Apr
W17: 20-Apr
W29: 13-Jul
W31: 27-Jul
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
-40% -40%
Mar
Apr
Jan
May
Jun
Jul
Feb
-60%
W37: 7-Sep
W11: 09-Mar
W13: 23-Mar
W3: 13-Jan
W5: 27-Jan
W7: 10-Feb
W9: 24-Feb
W15: 06-Apr
W17: 20-Apr
W19: 04-May
W21: 18-May
W29: 13-Jul
W31: 27-Jul
W33: 10-Aug
W35: 24-Aug
W1: 30-Dec
W23: 01-Jun
W25: 15-Jun
W27: 29-Jun
Week Starting Dates Month
Respiratory system Antineoplastic and immunomodulating agents Week Starting Dates
Antineoplastic and immunomodulating agents Musclo-skeletal system Over-the-Counter Drugs (OTC)
Cardiovascular system Antiparasitic products, insecticides and repellents Personal Care (PEC)
Blood and blood forming organs Cardiovascular system Patient Care (PAC)
Alimentary tract and metabolism Blood and blood forming organs Nutrition (NTR)
*Top in terms of YTD Growth; Units Growth Latest week 2020 vs. 2019; Source: IQVIA weekly sell out data – Week 1 2020 starting 30/12/2019 | Retail pharmacy panel – captures sales of products at retail pharmacies
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 29In the UK, overall promotion has shown positive growth compared to 2019
with majority share contributed by E-mails and Postal mailing
Promotional volume share and growth
Promotional volume share by channel % Change in promotional volume by channel
September* 2019 – September* 2020
3% 1%
6% -89%
28% 8%
3% -59%
1% 3% 419%
2%
296%
51%
31%
2,818%
83%
33% -7%
channels
27%
total
All
12%
September September
2019 2020
F2F Detailing E-Detailing E-meetings Postal Mailing
F2F Meeting Phone Detailing E-mail
*30 day period to 13/09
Source: IQVIA European Thought Leadership; ChannelDynamics 13/09/2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 30Agenda
1 Taking stock: An assessment of 2020 for the EU5 pharma market
2 Latest Sales Trends & HCP engagement across the EU5 Countries
3 Lessons for 2021
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 31We are only at the beginning of the economic crisis and the extended
healthcare system crisis
We face a dual challenge:
Health systems are both strained Healthcare systems
Payer constraints and constrained stretched
Patient out of pocket
Uncertainty and risk
constraints
Economic
Healthcare
crisis
system crisis
(2008-13,
(2020-)
2020--)
Public investment Increasingly remote
challenges healthcare provision
Private investment Risk and uncertainty enhancers: Different strategic
challenges • Second/extended waves healthcare priorities
• Timing and success of vaccine deployment
• Healthcare system constraints and resilience
• Depth/duration of economic crisis
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 32Pharma will need to adapt to thrive, and the strategic plan for 2020s must be
revised across the value chain
COVID impact timing COVID impact focus
✓ Local precision and coordination
GTM Model Near term ✓ Call-center based remote engagement
✓ Scientific/clinically focused field-team
Patient ✓ Enhance support for patients within new care sites
Support and Near term ✓ Strengthen pathways and guidelines to empower patients in care seeking behaviors
Engagement ✓ Remote monitoring and tele-health continuation
✓ Plan for new evidence requirements
Pricing and
Near term ✓ Accelerated focus on value demonstration
Market Access
✓ Regulators more responsive to change
Regulatory/
Near/mid term ✓ Long-term follow-up COVID-19 patients
Safety
✓ Evidence on COVID-19 impact
Near term (execution) ✓ Refocus portfolio strategy on high-unmet need areas
R&D/Portfolio
Long term (portfolio ✓ Innovative use of RW evidence
Strategy
choice) ✓ Tech-enabled execution
Supply and ✓ Consider domestic/collaborative manufacturing to prevent any supply issues or
Mid/long term
Manufacturing policy changes
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 33Three focus areas will redefine how companies prepare for excellent launch
Patient HCP Evidence
journey engagement and value
• A backlog of undiagnosed and treated • HCP/pharma engagement volume fell • Payers budget pressured in the coming
patients must be addressed and went remote – with recovery, economic crisis and will raise the bar of
engagement mix is still more remote evidence for access
• Opportunities for patients to receive new
or switch prescriptions must be rebuilt • HCPs are time pressured as they • Meaningful engagement with HCPs and
address ongoing pandemic crisis and health systems needs a strong stream of
• Some patient movement to remote
treatment backlogs effective RWE demonstrating utility and
treatment will be permanent
value in post pandemic environment
• HCPs expect patient treatment pattern
change and look to pharma for support
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 34Excellent launches had a significantly higher share of digital promotion in
our COVID-19 world
Overall levels of digital promotion have increased since 2018, but the conclusion remains
2018 Study 2020 Study
Avg. digital share of promo volume across 1st four quarters Avg. digital share of promo volume across 1st four quarters
following launch following launch
Top 7 developed: New Active Substances 2012-2016 Top 7 developed: New Active Substances 2014-2018
30%
30 30
25 25 24%
22%
20 20 18%
16%
15 13% 15
10 10
5 5
0 0
International All Other Specialty All Other Primary Care All other
Top Sellers Launches International Specialty International Primary Care
(All Specialty) Top Sellers Launches Top Sellers Launches
Source: IQVIA European Thought Leadership; ChannelDynamics Q3 2017; MIDAS Q3 2017; ChannelDynamics MAT Q1 2020; MIDAS MAT Q1 2020; Rx-only
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 35COVID-19 is an accelerator of change – the longer restrictions and
uncertainty prevail, the more drastic change can be expected
COVID-19 crisis caused significant decline in patient load and a diagnosis backlog, impacting new treatments
and switches, and implications for the launches entering the market in 2020 and beyond
Risk and uncertainty challenges forward planning. Healthcare system fragility, limits pharma’s ability to interact
with physicians at a time where its support with information and services essential
Long-term economic crisis will pressure healthcare budgets and require more compelling product evidence,
and pharma services for HCPs and patients navigating healthcare system change
A massive reduction of F2F interactions, and growth remote HCP-patient and pharma-HCP interaction – recent
experience increases digital capabilities and acceptance of digital engagement
Pharma needs to adapt team structures, capabilities, processes and tools to become more agile, digitally
savvy, more precise and faster in decision making
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 36Q&A
Sarah Rickwood, Natalie Harb
Vice President, Senior Principal,
European Marketing and Thought Leadership Global Analytics Solutions
© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. 37Upcoming Webinar’s
• We will continue with our monthly webinars and below we have outlined the key themes & dates for each webinars:
- 20th Oct: COVID-19 Implications on the Dynamic Market and Patient Backlog
- 24th Nov: Pandemic Impact on Innovative Launch and Launch Excellence Post Pandemic
• In October’s webinar we will also be sharing results from our 3rd survey that looks at the Impact of COVID-19 on Cancer
Treatment across the EU 5 countries
For more information on IQVIA’s COVID-19 perspectives, please visit:
https://www.iqvia.com/solutions/commercialization/covid-19-and-commercialization
COVID-19 Market Impact - Cross Country Report - 28th September 2020 | Copyright 2020 IQVIA. All rights reserved. 38Appendix
39The EU5 countries also exhibited similar trends of pandemic pharma sales
with varying degrees across the countries
Pharma Sales in Standard Units – Retail + Hospital market
Pharma sales in Italy (Mn SU/day) Pharma sales in Germany (Mn SU/day) Pharma sales in Spain (Mn SU/day)
250 250 250
200 200 200
150 150 150
100 100 100
50 50 50
0 0 0
Mar-19
Sep-19
Nov-19
Mar-20
Mar-19
Sep-19
Nov-19
Mar-20
Mar-19
Sep-19
Nov-19
Mar-20
Jan-19
May-19
Jul-19
Jan-20
May-20
Jul-20
Jan-19
May-19
Jul-19
Jan-20
May-20
Jul-20
Jan-19
May-19
Jul-19
Jan-20
May-20
Jul-20
Pharma sales in France (Mn SU/day) Pharma sales in UK (Mn SU/day)
250 250
200 200
150 150
100 100
50 50
0 0
Mar-19
Mar-20
Mar-19
Mar-20
Sep-19
Nov-19
Sep-19
Nov-19
Jan-19
May-19
Jul-19
Jan-20
May-20
Jul-20
Jan-19
May-19
Jul-19
Jan-20
May-20
Jul-20
Source: IQVIA European Thought Leadership, MIDAS MTH Jun 2020
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 40Thank You
Appendix: Data Sources
and Methodology
42IQVIA Sales Data Offerings Used and Methodology (1/2)
Geographic scope of Measures used
Data source Frequency Data source description Calculations applied
data used in this report for analysis
Weekly Sell-out Weekly Details on sales of products • Italy: Rx and CH • Italy: Units Italy, Germany, Spain, France:
Data dispensed at retail pharmacies markets • Germany: Units • Units Growth Jan 2020 vs 2019 – To provide
(Pharmatrend, This includes both prescription • Germany: Rx and CH base view of the market from pre COVID-19
Flashtrend) • Spain: Units
and non-prescription products markets period in the year 2020
• France: Units
Prescription products are • Spain: Rx and CH • Units Growth Latest week 2020 vs 2019 –
classified using ATC markets • UK: Rx counts To provide the latest trend in the market to
classification understand the dynamic changes in trends
• France: Rx and CH
Consumer health products markets • Units Growth YTD 2020 vs 2019 – To provide
cover products from Over the the YTD trend in the market to understand the
• UK: Rx market
Counter drugs, Personal Care, longer term changes in trends
Patient Care and Nutrition UK: Rx market
categories
• Rx Growth Latest week Rx 2020 vs Average
Rx for Jan 2020 – To provide comparison of
latest market scenario against Jan 2020 (pre
COVID-19 period) as base where 2019 data
was unavailable
• Rx Growth YTD average weekly Rx 2020 vs
Average weekly Rx for Jan 2020 – To
provide comparison of YTD sales trends in
2020 against Jan 2020 (pre COVID-19 period)
as base where 2019 data was unavailable
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 43IQVIA Sales Data Offerings Used and Methodology (2/2)
Geographic scope of Measures used
Data source Frequency Data source description Calculations applied
data used in this report for analysis
Weekly Sell-in Weekly Details on purchase of • UK consumer health • UK: Units UK: CH market
Data products by retail pharmacies market • Units Growth Jan 2020 vs 2019 – To provide
Our current scope covers base view of the market from pre COVID-19
consumer health products only period in the year 2020
• Units Growth Latest week 2020 vs 2019 –
To provide the latest trend in the market to
understand the dynamic changes in trends
• Units Growth YTD 2020 vs 2019 – To provide
the YTD trend in the market to understand the
longer term changes in trends
MIDAS Data Monthly Details on hospital panel retail • Italy hospital market • Italy: Units Italy, Germany, Spain, France, UK:
sales
• Germany hospital • Germany: Units • Units Growth Jan 2020 vs 2019 – To provide
market base view of the market from pre COVID-19
• Spain: Units
period in the year 2020
• Spain hospital market • France: Units
• Units Growth Latest month 2020 vs 2019 –
• France hospital market • UK: Units To provide the latest trend in the market to
• UK hospital market understand the dynamic changes in trends
• Units Growth YTD 2020 vs 2019 – To provide
the YTD trend in the market to understand the
longer term changes in trends
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 44Sources from secondary data research Number of Reported COVID-19 Infections in EU5 (Slide 15) Italy: • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU) • The Civil Protection Department, Govt of Italy http://www.protezionecivile.it/attivita-rischi/rischio-sanitario/emergenze/coronavirus Germany: • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU) • Robert Koch-Institut https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html Spain: • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU) • Ministerio de Sanidad, Consumo y Bienestar Social, Govt of Spain https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/situacionActual.htm France: • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU) • Santé Publique France, Govt of France https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau- coronavirus-sars-cov-2-covid-19-france-et-monde UK: • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU) • Department of Health and Social Care and Public Health England, Govt of UK https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public#number-of-cases Please note: IQVIA is not accountable for the accuracy of information from external data sources COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 45
Sources from secondary data research COVID-19 patient insights (Slide 16) Italy: • https://www.epicentro.iss.it/ • http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5057 • http://www.salute.gov.it/nuovocoronavirus • https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_7_september_2020.pdf • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU): https://coronavirus.jhu.edu/ Germany: • https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html?nn=13490888 • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU): https://coronavirus.jhu.edu/ Spain: • https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx • https://cnecovid.isciii.es/covid19/ • https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_209_COVID-19.pdf • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU): https://coronavirus.jhu.edu/ France: • https://www.santepubliquefrance.fr/recherche/#search=COVID%2019%20%20%20point%20epidemiologique&publications=donn%C3%A9es®ions=National&sort=date • Center for System Science and Engineering (CSSE) at John Hopkins University (JHU): https://coronavirus.jhu.edu/ Please note: IQVIA is not accountable for the accuracy of information from external data sources COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 46
Channel Definitions (Slides 22,24,26,28,30)
F2F Detailing: Sales Rep face-to-face detailing
Face to face
interactions
F2F Meetings: Meetings, events, congresses, seminars
E-Detailing: Online presentations - live with a rep or automated, self guided
Phone Detailing: Telephone communication with reps
Remote
E-Meetings: Streaming video – live webinar or pre-recorded webcast
interactions
Email: Opened email communication
Postal: Opened paper mail received by post
COVID-19 EU5 Webinar – Sept 2020| Copyright 2020 IQVIA. All rights reserved. 47You can also read
